tbuckley/cabot-search huggingface dataset:
Abstract 1739: Diminished <i>SKP1</i> or <i>CUL1</i> expression induces chromosome instability in high-grade serous ovarian cancer precursor cells
Authors: Chloe C. Lepage, Mark W. Nachtigal, Kirk J. McManus
Journal: Cancer Research (2019)

Abstract High-grade serous ovarian cancer (HGSOC) is the most common ovarian cancer subtype as well as the most lethal. High mortality rates associated with HGSOC are in part due to a lack of reliable early detection methods and effective therapies. Importantly, chromosome instability (CIN; an increased rate of chromosome gains or losses), is causally implicated in cancer development, progression, and resistance to treatment, and is just beginning to be evaluated in an HGSOC context. Overexpression of Cyclin E1 protein induces CIN and genomic amplification contributes to HGSOC pathogenesis in 20% of HGSOC patients. Cyclin E1 protein levels are normally regulated in a cell cycle-dependent manner by the SCF (SKP1-CUL1-FBOX) complex, an E3 ubiquitin ligase that targets substrates for proteolytic degradation. In cases where genomic amplification is absent, we hypothesize that loss of SCF complex function stemming from diminished expression of individual SCF complex components underlies increases in Cyclin E1 levels and induces CIN. The current study focuses on the SCF complex components SKP1 and CUL1 and characterizes their role in early HGSOC pathogenesis within a fallopian tube secretory epithelial cell model (FT; a cell of origin for HGSOC). Using siRNA-based approaches, we show that diminished SKP1 and CUL1 expression results in increased Cyclin E1 protein levels in FT cells. Using quantitative imaging microscopy techniques, we further identify statistically significant changes in CIN-associated phenotypes within the silenced populations, including changes in nuclear areas, increases in micronucleus formation (i.e. small DNA-containing bodies outside of the primary nucleus), and increases in numerical chromosome abnormalities identified in mitotic chromosome spreads. Thus, the current study explores the early origins of HGSOC and identifies SKP1 and CUL1 as two promising new molecular players that may contribute to CIN to drive FT cell transformation, drug resistance and disease recurrence. Citation Format: Chloe C. Lepage, Mark W. Nachtigal, Kirk J. McManus. Diminished SKP1 or CUL1 expression induces chromosome instability in high-grade serous ovarian cancer precursor cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1739.
THE RELATION BETWEEN TUMORS IN PLANTS AND IN ANIMALS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rapid Routine Measurement of Height, Weight and Vision
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrections to “Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy”
Authors: C.E. McCoach, G.M. Blumenthal, L. Zhang, A. Myers, S. Tang, R. Sridhara, P. Keegan, R. Pazdur, R.C. Doebele, D. Kazandjian
Journal: Annals of Oncology (2018)

Ann Oncol 2017; 28: 2707–2714 (doi: 10.1093/annonc/mdx414) In the original article, the funding information was omitted. It should have read as follows: This work was supported in part by a Career Development Award from the University of Colorado SPORE in Lung grant (#P50 058187) from the National Cancer Institute. The original article has been corrected online. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyAnnals of OncologyVol. 28Issue 11PreviewResponse Evaluation Criteria in Solid Tumors (RECIST) permits rapid evaluation of new therapeutic strategies in cancer. However, RECIST does not capture the heterogeneity of response in highly active therapies. Depth of tumor response may provide a more granular view of response. We explored the association between, depth of response (DepOR), with overall survival (OS) and progression-free survival (PFS) for patients with NSCLC being treated with an ALK inhibitor (ALKi) or an anti-PD-1 antibody (Ab). Full-Text PDF Open Archive
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene
Authors: Ana O. Hoff, Philip Catala-Lehnen, Pamela M. Thomas, Matthias Priemel, Johannes M. Rueger, Igor Nasonkin, Allan Bradley, Mark R. Hughes, Nelson Ordonez, Gilbert J. Cote, Michael Amling, Robert F. Gagel
Journal: Journal of Clinical Investigation (2002)

Calcitonin (CT) is a known inhibitor of bone resorption. Calcitonin gene-related peptide-alpha (CGRPalpha), produced by alternative RNA processing of the CT/CGRP gene, has no clearly defined role in bone. To better understand the physiologic role of the CT/CGRP gene we created a mouse in which the coding sequences for both CT and CGRPalpha were deleted by homologous recombination. The CT/CGRP(-/-) knockout (KO) mice procreated normally, there were no identifiable developmental defects at birth, and they had normal baseline calcium-related chemistry values. However, KO animals were more responsive to exogenous human parathyroid hormone as evidenced by a greater increase of the serum calcium concentration and urine deoxypyridinoline crosslinks, an effect reversed by CT and mediated by a greater increase in bone resorption than in controls. Surprisingly, KO mice have significantly greater trabecular bone volume and a 1.5- to 2-fold increase in bone formation at 1 and 3 months of age. This effect appears to be mediated by increased bone formation. In addition, KO mice maintain bone mass following ovariectomy, whereas wild-type mice lose approximately one-third of their bone mass over 2 months. These findings argue for dual roles for CT/CGRP gene products: prevention of bone resorption in hypercalcemic states and a regulatory role in bone formation.
Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study
Authors: Jerome Boursier, Rohit Loomba, Quentin Anstee, Stephen Harrison, Arun Sanyal, Mary Rinella, Zobair Younossi, Zachary Goodman, Pierre Bedossa, Céline Fournier, Michael Stenkilsson, Reshma Shringarpure, Luna Zaru, Aditya Venugopal, Leigh MacConell, Vlad Ratziu
Journal: Journal of Hepatology (2020)
Intravenous Diazepam Administration
Authors: John D. Barker
Journal: JAMA (1973)

<h3>To the Editor.—</h3> One predisposing factor was omitted in the article by Langdon et al (223:184, 1973) describing thrombophlebitis following intravenous injection of diazepam. In the package insert, the manufacturer cautions that injectable diazepam (Valium) should not be mixed or diluted with other solutions or drugs, nor added to intravenous fluids. The manufacturer responded to our inquiry concerning the reason for this restriction, by explaining that injectable diazepam has very low solubility in water and aqueous solutions. For this reason, it was buffered with a formulation including benzoate sodium. Dilution of the solvent system results in precipitation of the diazepam. If the solution is then acidified, a precipitate of benzoic acid will result, which may coprecipitate with the drug. Langdon et al do not describe whether they injected the drug directly into the vein or through a tube. Since, in some of their patients, more than 10 mg was injected, the
Patients with metastatic papillary renal cell carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database.
Authors: Jae-Lyun Lee, Maya Gottfried, Natalie Maimon, Hans J. Hammers, Mario A. Eisenberger, Michael Anthony Carducci, Victoria J. Sinibaldi, Victoria Neiman, Eli Rosenbaum, David Sarid, Eliahu Gez, Avivit Peer, Avishay Sella, Wilmosh Mermershtain, Keren Rouvinov, Raanan Berger, Daniel Keizman
Journal: Journal of Clinical Oncology (2014)

e15547 Background: The VEGFR inhibitor sunitinib is a standard tx for metastatic clear cell RCC. Data on the activity of sunitinib in metastatic non clear cell RCC, is limited by small or heterogeneous (mixed histology or targeted therapies) studies, that revealed a lower antitumor activity than in patients with clear cell histology. We aimed to analyze the activity of sunitinib in a large international cohort of patients with metastatic papillary RCC, and to characterize patients who may benefit for this therapy. Methods: Records from metastatic papillary RCC patients treated with sunitinib in 10 centers across 3 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and clinical outcome were performed using Cox regression. Results: Between 2004-2013, 74 patients (median age 60, 68% male) with metastatic papillary RCC were treated with sunitinib. 78% had a prior nephrectomy. HENG risk was good 11%, intermediate 56%, and poor 33%. 21% were active smokers, and 31% users of angiotensin system inhibitors. 24% and 41% had liver and bone metastases, respectively. 55% had a pre-treatment neutrophil to lymphocyte ratio (NLR) >3. 40% had dose reduction/treatment interruption. Sunitinib induced hypothyroidism and hypertension (HTN) occurred in 30% and 43%, respectively. 70% achieved a clinical benefit (partial response + stable disease), while 30% had disease progression within the first 3 months of therapy. Median progression free survival (PFS) and overall survival (OS) were 5 and 12 months, respectively. 27% had a PFS ≥ 1 year, and 26% survived ≥ 2 years. Factors associated with PFS were sunitinib induced HTN (HR 0.31, p=0.002), pre-treatment NLR >3 (HR 5.3, p=0.001), and active smoking (HR 2.5, p=0.01). Factors associated with OS were sunitinib induced hypothyroidism (HR 0.4, p=0.024), past nephrectomy (HR 0.41, p=0.02), pre-treatment NLR >3 (HR 2.25, p=0.036), and active smoking (HR 2.3, p=0.027). Conclusions: Clinicopathologic factors may be used to identify patients with metastatic papillary RCC who may benefit from sunitinib tx. A prolonged PFS and OS were noted in 26-27% of patients.
Abstract 10770: Curcumin Mitigates the Severity of Post-Resuscitation Myocardial Dysfunction Caused by Epinephrine in a Rat Cardiac Arrest Model
Authors: Zhengfei Yang, Jiangang Wang, Lu Yin, Shen Zhao, Ziren Tang, Jena Cahoon, Wanchun Tang
Journal: Circulation (2015)

Introduction: Epinephrine significantly increases the severity of post-resuscitation myocardial dysfunction (PRMD) and reduces the duration of survival. The cardioprotective effect of curcumin against catecholamine-induced cardiotoxicity has been established. In the present study, we investigated the effects of curcumin on PRMD caused by epinephrine in a rat model of cardiac arrest. Hypothesis: Curcumin reduces the severity of PRMD caused by epinephrine. Methods: Twenty-four male Sprague-Dawley rats weighing between 450-550g were randomized into three groups: 1) Placebo group; 2) Epinephrine (20ug/kg) group; 3) Curcumin (100 mg/kg) pretreatment + epinephrine (20ug/kg) group. Ventricular fibrillation (VF) was then induced. After 8 mins of VF, CPR was initiated for 8 mins, and defibrillation was then attempted. Myocardial function was measured by echocardiography at baseline and hourly for 4 hours following successful resuscitation. Results: All animals except for two in the placebo group were resuscitated. Post-resuscitation myocardial function was significantly impaired in all animals. Significantly worse myocardial function was observed in the Epinephrine group in comparison with the two other groups (Figure). However, myocardial function was significantly better in the animals treated with curcumin when compared with those in the two other groups (Figure). Conclusion: In a rat cardiac arrest model, curcumin reduced the severity of PRMD caused by epinephrine.
Medical Sport
Authors: Paul W. Brown
Journal: JAMA (1971)

<h3>To the Editor.—</h3> The following short case history was recently discovered in a very ancient work and is given further to support and illustrate the growing value of the practice of sports medicine. A prominent gladiator had become decreasingly proficient in decapitating Christians. He noted that in swinging a sword and in casting a javelin a sharp lancinating pain over the lateral aspect of his right (dominant) elbow interfered with follow through of the stroke. On consultation with his coach, his trainer and with several of his opponents who had not completely lost their heads, the following observation was consistently noted. When swinging or throwing the weapon he would wince with pain as the stroke or throw neared completion and would then grasp his right elbow with his left hand and massage the joint vigorously. Physical examination confirmed the suspicions of a panel of sports medicine physicians appointed by the
OAKLAND COUNTY, MICH., MEDICAL EMERGENCY RELIEF
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Independent predictors of overall survival and recurrence in biphenotypic hepatocellular cancer.
Authors: Manik Amin, Ling Chen, Elizabeth Brunt, Neeta Vachhajarani, Maria Majella Doyle, William Chapman, Kathryn Fowler, Nael Saad, Benjamin R. Tan
Journal: Journal of Clinical Oncology (2014)

e15093 Background: Biphenotypic hepatocellular cancer (BPHCC), which is a combined hepatocellular cancer (HCC) and cholangiocarcinoma (CC), is a rare form of primary liver cancer, whose long term prognosis is extremely poor as compared to either HCC or CC alone. Little is known about the recurrence rates and predictors of recurrence in BPHCC. Our objective was to 1) identify both overall survival and recurrence rates after primary resection or systemic and liver directed therapies and 2) to evaluate the independent predictors of survival and recurrence. Methods: Our Hepatobiliary Registry identified 65 patients with BPHCC from February 1999 till April 2013 at Siteman Cancer Center, Washington University, St. Louis MO. We conducted univariate Kaplan-Meier survival analysis and multivariable Cox proportional hazards regression to identify factors independently associated with overall survival. We also conducted multivariable logistic regression analysis to identify factors independently associated with recurrence. Results: Of the 65 patients in our study, 18 (28%) with prior resection, 2 (3%) after OLT, 45 (69%) ineligible for surgery, 40 (62%) were treated with chemotherapy, 17 (26%) with liver directed therapies. Overall survival was 39.2 % at 1 year. Independent factors associated with survival were: smoking (HR 2.84, 95% CI 1.29-6.23, p = 0.0089), tumor thrombus (HR 5.45, 95% CI 2.05-14.50, p = 0.0007), any liver directed treatment (HR 3.01, 95% CI 1.21-7.48, p = 0.0175), multiple satellite lesions (HR 3.17, 95% CI 1.71-8.58, p = 0.025) and prior tumor resection (HR 2.65, 95% CI 1.16-6.03, p = 0.020). Risk of recurrence was independently predicted by sex (OR 3.98, 95% CI 1.30-12.15, p = 0.015), multiple satellite lesions (OR 15.42, 95% CI 2.68-88.62, p = 0.0076). Conclusions: Patients with biphenotypic cancers have a devastating overall survival. smoking, resection of primary cancer, tumor thrombus and satellite lesions, liver directed treatments were predictors of survival whereas, sex, satellite lesions and lymph node resection strongly predicted recurrence. In this rare form of cancer, this is the largest study to identify factors associated with overall survival and recurrence.
COMMON COLDS AND THE WEATHER
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Whiplash injury.
Authors: J M Pearce
Journal: BMJ (1990)

low plasma concentrations of free cyanide dicobalt edetate itself can be toxic.'A second approach is to use sodium nitrite, which converts haemoglobin to methaemoglobin, though in a patient whose oxygen delivery is already compromised by a high carboxyhaemoglobin concentration a further decrease in the haemoglobin available for oxygen transport can be dangerous.We therefore recommend use of the safer intravenous antidote sodium thiosulphate,3 whose distribution is enhanced by the vasodilator amyl nitrite.4
Stent + Radiation No Sure Cure for Stenosis
Authors: M. Mitka
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sodium chloride preference in essential hypertension
Authors: P. J. Schechter
Journal: JAMA (1973)

Sodium chloride preference was determined in ten patients with essential hypertension and in 12 normal volunteers. All exhibited normal detection and recognition thresholds for the taste of sodium chloride. All were placed on a constant dry diet containing 9 mEq of Na+ and given, as their only source of fluids, a choice of drinking either distilled water or 0.15 M sodium chloride. Patients with essential hypertension consumed a markedly greater proportion of their total fluid intake as saline (38.2% vs 10.6%, average daily preference over one week) and also showed a greater total fluid intake (1,269 ml vs 668 ml, average daily intake over one week). The hypertensive patients consumed more than four times as much salt as did the normal volunteers.
Radiation Epidemiology: Old and New Challenges
Authors: Roy E. Shore
Journal: Environmental Health Perspectives (1989)

Over the last 40 years the amount of knowledge about human radiation effects has increased dramatically. During that interval, radiation epidemiologists have documented a number of additional types of radiation-induced cancer and have established rough estimates of the magnitude of cancer risks. Nevertheless, we currently have inadequate knowledge about a number of factors that help define the magnitude of radiation risks. These include questions of estimating risk over the lifetime, shapes of dose-effect curves, magnitude of risks at low doses, potentiation between radiation and other agents, and the nature and role of host susceptibility factors. Data from various studies are used to illustrate these questions.